These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 15992586)

  • 41. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
    Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
    Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tonic modulation of inhibition by dopamine D4 receptors in the rat hippocampus.
    Romo-Parra H; Aceves J; Gutiérrez R
    Hippocampus; 2005; 15(2):254-9. PubMed ID: 15476261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors.
    Malmberg A; Jackson DM; Eriksson A; Mohell N
    Mol Pharmacol; 1993 May; 43(5):749-54. PubMed ID: 8099194
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms.
    Schetz JA; Chu A; Sibley DR
    J Pharmacol Exp Ther; 1999 May; 289(2):956-64. PubMed ID: 10215675
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
    Wu WL; Burnett DA; Spring R; Greenlee WJ; Smith M; Favreau L; Fawzi A; Zhang H; Lachowicz JE
    J Med Chem; 2005 Feb; 48(3):680-93. PubMed ID: 15689153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine receptor regulation of Ca2+ levels in individual isolated nerve terminals from rat striatum: comparison of presynaptic D1-like and D2-like receptors.
    Wu J; Dougherty JJ; Nichols RA
    J Neurochem; 2006 Jul; 98(2):481-94. PubMed ID: 16805841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning.
    Stewart AO; Cowart MD; Moreland RB; Latshaw SP; Matulenko MA; Bhatia PA; Wang X; Daanen JF; Nelson SL; Terranova MA; Namovic MT; Donnelly-Roberts DL; Miller LN; Nakane M; Sullivan JP; Brioni JD
    J Med Chem; 2004 Apr; 47(9):2348-55. PubMed ID: 15084133
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor.
    Kulagowski JJ; Broughton HB; Curtis NR; Mawer IM; Ridgill MP; Baker R; Emms F; Freedman SB; Marwood R; Patel S; Patel S; Ragan CI; Leeson PD
    J Med Chem; 1996 May; 39(10):1941-2. PubMed ID: 8642550
    [No Abstract]   [Full Text] [Related]  

  • 49. The discovery of PD 89211 and related compounds: selective dopamine D4 receptor antagonists.
    Pugsley TA; Shih YH; Whetzel SZ; Zoski K; Van Leeuwen D; Akunne H; Mackenzie R; Heffner TG; Wustrow D; Wise LD
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):219-26. PubMed ID: 11817497
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D4 receptor antagonists as potential antipsychotic agents.
    Unangst PC; Capiris T; Connor DT; Heffner TG; MacKenzie RG; Miller SR; Pugsley TA; Wise LD
    J Med Chem; 1997 Aug; 40(17):2688-93. PubMed ID: 9276014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) receptor with excellent selectivity over ion channels.
    Carling RW; Moore KW; Moyes CR; Jones EA; Bonner K; Emms F; Marwood R; Patel S; Patel S; Fletcher AE; Beer M; Sohal B; Pike A; Leeson PD
    J Med Chem; 1999 Jul; 42(14):2706-15. PubMed ID: 10411491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.
    Dutta AK; Venkataraman SK; Fei XS; Kolhatkar R; Zhang S; Reith ME
    Bioorg Med Chem; 2004 Aug; 12(16):4361-73. PubMed ID: 15265488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions.
    Zhang K; Davids E; Tarazi FI; Baldessarini RJ
    Psychopharmacology (Berl); 2002 Apr; 161(1):100-6. PubMed ID: 11967637
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat.
    Schmidt HD; Pierce RC
    Neuroscience; 2006 Oct; 142(2):451-61. PubMed ID: 16844308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacology of a human dopamine D4 receptor expressed in HEK293 cells.
    Lawson CF; Mortimore RA; Schlachter SK; Smith MW
    Methods Find Exp Clin Pharmacol; 1994 Jun; 16(5):303-7. PubMed ID: 7934308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activation of dopamine D4 receptors modulates [3H]GABA release in slices of the rat thalamic reticular nucleus.
    Florán B; Florán L; Erlij D; Aceves J
    Neuropharmacology; 2004 Mar; 46(4):497-503. PubMed ID: 14975673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopamine agonist-induced penile erection and yawning: a comparative study in outbred Roman high- and low-avoidance rats.
    Sanna F; Corda MG; Melis MR; Piludu MA; Löber S; Hübner H; Gmeiner P; Argiolas A; Giorgi O
    Pharmacol Biochem Behav; 2013 Aug; 109():59-66. PubMed ID: 23664901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT(4) receptor.
    Mikami T; Komada T; Sugimoto H; Suzuki K; Ohmi T; Kimura N; Naganeo R; Nakata E; Nakatani K; Toga T; Eda H; Sakakibara M
    Eur J Pharmacol; 2009 May; 609(1-3):5-12. PubMed ID: 19285067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction of the novel antipsychotic drug amperozide and its metabolite FG5620 with central nervous system receptors and monoamine uptake sites: relation to behavioral and clinical effects.
    Svartengren J; Pettersson E; Björk A
    Biol Psychiatry; 1997 Aug; 42(4):247-59. PubMed ID: 9270901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology.
    Schetz JA; Benjamin PS; Sibley DR
    Mol Pharmacol; 2000 Jan; 57(1):144-52. PubMed ID: 10617689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.